BioCryst Pharmaceuticals, Inc.
Methods of treating hematologic cancers
Last updated:
Abstract:
The present application relates to treatment of hematologic cancers, which treatments can include, e.g., administration of a purine nucleoside phosphorylase (PNP) inhibitor, an alkylating agent and/or an anti-CD20 agent, and related compositions and kits.
Status:
Grant
Type:
Utility
Filling date:
1 May 2019
Issue date:
7 Sep 2021